Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates for the treatment of non-alcoholic steatohepatitis
(NASH) and other chronic liver diseases, today announced it will
present data from two of its clinical development programs for NASH
at the NASH-TAG Conference 2021, taking place March 11-13, 2021.
“We are pleased to be invited by the NASH-TAG conference
organizers to give an oral presentation on the potential benefits
of targeting vascular adhesion protein-1 (VAP-1) inhibition for the
treatment of NASH, ahead of the initiation of our NASH clinical
trial for TERN-201, our highly selective VAP-1 inhibitor,” said
Erin Quirk, M.D., President and Chief Medical Officer of Terns. “In
2020, we presented data demonstrating that TERN-201 may have
advantages over other VAP-1 inhibitor candidates and we look
forward to showcasing the program with the hepatology community as
we continue to advance our clinical studies. We will also be
presenting data for our FXR agonist, TERN-101, demonstrating
increased histological resolution of liver steatosis, inflammation
and fibrosis in a preclinical NASH model. We expect to report
12-week clinical data from our Phase 2a LIFT Study of TERN-101 in
NASH patients in the third quarter of 2021.”
The details of Terns’ presentations are as follows:
Oral PresentationTargeting VAP-1 Inhibition in
NASHMarch 13, 20216:45 PM, MST
PosterLiver-distributed Farnesoid X Receptor
agonist TERN-101 is more efficacious in a mouse model of
non-alcoholic steatohepatitis than Obeticholic AcidAbstract #
13March 11-13
A copy of the presentations will be accessible in the Scientific
Publications section of the Terns website at
www.TernsPharma.com.
The NASH-TAG Conference is designed to bring together clinicians
and researchers in academia and the pharmaceutical industry for a
focused interactive educational update highlighting the most
relevant advances and challenges in the diagnosis and therapy of
NASH and liver fibrosis.
About TERN-201TERN-201 is a highly-selective
inhibitor of vascular adhesion protein-1 (VAP-1) that has
demonstrated sustained target engagement in clinical trials without
off-target liabilities associated with other VAP-1 inhibitors in
development. VAP-1 has been shown to be over-expressed in the
livers of NASH patients in response to local lipotoxicity and liver
injury. TERN-201 may have advantages over other development
candidates because it is highly specific for VAP-1 inhibition and
has minimal potential for off-target effects. Terns plans to start
its Phase 1b clinical trial of TERN-201 in NASH patients in the
first half of 2021 and expects data in the first half of 2022.
Terns received Fast Track designation from the FDA for TERN-201 for
the treatment of NASH in August 2020.
About TERN-101TERN-101 is a liver-distributed,
non-bile acid FXR agonist that has demonstrated a differentiated
tolerability profile and improved target engagement, likely due to
its sustained FXR activation in the liver but only transient FXR
activation in the intestine. FXR is a nuclear receptor primarily
expressed in the liver, intestine and kidneys. FXR regulates
hepatic expression of various genes involved in lipid metabolism,
inflammation and fibrosis. Studies have demonstrated that there is
minimal overlap between liver and intestine FXR binding sites,
indicating potentially a high degree of tissue-specific FXR
function. Clinical studies of other FXR agonists have demonstrated
significant histological NASH improvements but have also resulted
in pruritus and adverse lipid changes. These tolerability issues
have generally been observed in Phase 1 clinical trials of other
FXR agonists in development and have been regarded as dose-limiting
toxicities, which are suboptimal for patients and can lead to
treatment discontinuation. However, in all four Phase 1 clinical
trials of TERN-101, none of the 119 subjects who received TERN-101
reported pruritus, and the serum lipid profiles among TERN-101
recipients were similar to placebo recipients even at high
doses.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates for the treatment of non-alcoholic
steatohepatitis, or NASH, and other chronic liver diseases. Terns’
programs are based on clinically validated and complementary
mechanisms of action to address the multiple hepatic disease
processes of NASH in order to drive meaningful clinical benefits
for patients. For more information, please visit
www.ternspharma.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements about
Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”)
within the meaning of the federal securities laws, including those
related to the Company’s expectations of timing and potential
results of the Company’s clinical trials and other development
activities and the potential utility and progress of the Company’s
product candidates in NASH. All statements other than statements of
historical facts contained in this press release, including
statements regarding the Company’s strategy, future financial
condition, future operations, projected costs, prospects, plans,
objectives of management and expected market growth, are
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results and the implementation of the
Company’s plans to vary materially, including the risks associated
with the initiation, cost, timing, progress and results of the
Company’s current and future research and development activities
and preclinical studies and clinical trials. In particular, the
impact of the COVID-19 pandemic on the Company’s ability to
progress with its research, development, manufacturing and
regulatory efforts, including the Company’s clinical trials for its
product candidates, will depend on future developments that are
highly uncertain and cannot be predicted with confidence at this
time, such as the ultimate duration of the pandemic, travel
restrictions, quarantines, social distancing and business closure
requirements in the United States and in other countries,
and the effectiveness of actions taken globally to contain and
treat the disease. These risks are not exhaustive. For a detailed
discussion of the risk factors that could affect the Company’s
actual results, please refer to the risk factors identified in the
Company’s SEC reports, including but not limited to its prospectus
dated February 4, 2021. Except as required by law, the Company
undertakes no obligation to update publicly any forward-looking
statements for any reason.
US Media Contact:Investor Relations
Contact:Mark Vignola investors@ternspharma.com
Media Contact: Cory
Trombleemedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2023 to Apr 2024